---
layout: post
title: "Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing"
date: 2026-02-05 19:01:04 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-21932
original_published: 2022-10-11 00:00:00 +0000
significance: 8.00
---

# Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 11, 2022 00:00 UTC
**Document Number:** 2022-21932

## Summary

The Director of the Center for Drug Evaluation and Research (Center Director) at the Food and Drug Administration (FDA or Agency) is proposing to refuse to approve a supplemental new drug application (sNDA) submitted by Vanda Pharmaceuticals, Inc. (Vanda), for HETLIOZ (tasimelteon) capsules, 20 milligrams (mg), in its present form. This notice summarizes the grounds for the Center Director's proposal and offers Vanda an opportunity to request a hearing on the matter.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/11/2022-21932/proposal-to-refuse-to-approve-a-new-drug-application-supplement-for-hetlioz-tasimelteon-opportunity)
- API: https://www.federalregister.gov/api/v1/documents/2022-21932

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
